中国小儿急救医学
中國小兒急救醫學
중국소인급구의학
CHINESE PEDIATRIC EMERGENCY MEDICINE
2009年
1期
20-22
,共3页
孟陆亮%邹丽萍%丁瑛雪%王颖%马明圣%吴沪生%张五昌
孟陸亮%鄒麗萍%丁瑛雪%王穎%馬明聖%吳滬生%張五昌
맹륙량%추려평%정영설%왕영%마명골%오호생%장오창
伴中央-颞区棘波的儿童良性癫(癎)%药物治疗%儿童
伴中央-顳區棘波的兒童良性癲(癎)%藥物治療%兒童
반중앙-섭구극파적인동량성전(간)%약물치료%인동
Benign childhood epilepsy with centro-temporal spikes%First antiepileptic drug%Children
目的 丙戊酸钠、卡马西平、托吡酯被公认为是目前广谱的抗癫(癎)药物,临床上均可用于治疗伴中央-颞区棘波的儿童良性癫(癎)(BECT).本研究旨在比较这些药物对儿童BECT的治疗效果,筛选临床单药治疗的首选药物.方法 通过84例药物治疗BECT病例(丙戊酸钠31例,卡马西平31例,托吡酯22例)的回顾性分析,从首药治疗失败时间、首治发作控制率、药物不良反应三个方面,对托吡酯、卡马西平、丙戊酸钠的治疗效果进行比较.结果 托吡酯、卡马西平、丙戊酸钠的首药治疗失败时间分别为3.00个月[0.75～12.00]、8.00个月[2.50～32.00]、5.00个月[1.25～11.75],三者差异无显著性(P=0.463).癫(癎)发作控制率托吡酯、卡马西平、丙戊酸钠分别为77.3%、83.9%、74.2%,差异无显著性(X2=1.475,P=0.478).托吡酯有较高的药物不良反应发生率,与丙戊酸钠(X2=8.717,P=0.003)和卡马西平(X2=7.105,P=0.008)相比差异有显著性,丙戊酸钠与卡马西平相比差异无显著性(X2=0.111,P=0.74).结论 托吡酯、卡马西平、丙戊酸钠均可作为儿童BECT单药治疗的首选药物.
目的 丙戊痠鈉、卡馬西平、託吡酯被公認為是目前廣譜的抗癲(癎)藥物,臨床上均可用于治療伴中央-顳區棘波的兒童良性癲(癎)(BECT).本研究旨在比較這些藥物對兒童BECT的治療效果,篩選臨床單藥治療的首選藥物.方法 通過84例藥物治療BECT病例(丙戊痠鈉31例,卡馬西平31例,託吡酯22例)的迴顧性分析,從首藥治療失敗時間、首治髮作控製率、藥物不良反應三箇方麵,對託吡酯、卡馬西平、丙戊痠鈉的治療效果進行比較.結果 託吡酯、卡馬西平、丙戊痠鈉的首藥治療失敗時間分彆為3.00箇月[0.75～12.00]、8.00箇月[2.50～32.00]、5.00箇月[1.25～11.75],三者差異無顯著性(P=0.463).癲(癎)髮作控製率託吡酯、卡馬西平、丙戊痠鈉分彆為77.3%、83.9%、74.2%,差異無顯著性(X2=1.475,P=0.478).託吡酯有較高的藥物不良反應髮生率,與丙戊痠鈉(X2=8.717,P=0.003)和卡馬西平(X2=7.105,P=0.008)相比差異有顯著性,丙戊痠鈉與卡馬西平相比差異無顯著性(X2=0.111,P=0.74).結論 託吡酯、卡馬西平、丙戊痠鈉均可作為兒童BECT單藥治療的首選藥物.
목적 병무산납、잡마서평、탁필지피공인위시목전엄보적항전(간)약물,림상상균가용우치료반중앙-섭구극파적인동량성전(간)(BECT).본연구지재비교저사약물대인동BECT적치료효과,사선림상단약치료적수선약물.방법 통과84례약물치료BECT병례(병무산납31례,잡마서평31례,탁필지22례)적회고성분석,종수약치료실패시간、수치발작공제솔、약물불량반응삼개방면,대탁필지、잡마서평、병무산납적치료효과진행비교.결과 탁필지、잡마서평、병무산납적수약치료실패시간분별위3.00개월[0.75～12.00]、8.00개월[2.50～32.00]、5.00개월[1.25～11.75],삼자차이무현저성(P=0.463).전(간)발작공제솔탁필지、잡마서평、병무산납분별위77.3%、83.9%、74.2%,차이무현저성(X2=1.475,P=0.478).탁필지유교고적약물불량반응발생솔,여병무산납(X2=8.717,P=0.003)화잡마서평(X2=7.105,P=0.008)상비차이유현저성,병무산납여잡마서평상비차이무현저성(X2=0.111,P=0.74).결론 탁필지、잡마서평、병무산납균가작위인동BECT단약치료적수선약물.
Objective To piramate, Carbamazepine and Sodium valproate are generally acknowl-edged to be the current broad-spectrum antiepileptic drugs, which are used for the treatment of BECT. Our study aimed to compare the long-term effects of these drugs in patients with BECT and find the drug for monotherapy. Methods We conducted a retrospective study of 84 children with BECT to compare the thera-peutic effect of Topiramate, Sodium valproate and Carbamazepine by analyzing treatment failure time, seizure control rate and drug adverse effects. Results There was no difference among Topiramate,Sodium valproate and Carbamazepine in treatment failure time (P=0.463) and seizure control rate (X2=1.475, P=0.478), but patients taking Topiramate had a higher incidence of adverse events compared with those taking Sodium valproate(X2=8.717,P=0.003)or Carbamazepine (X2=7.105,P=0.008). Conclusion Topiramate,So-dium valproate and Carbamazepine could be the first antiepileptic drug in children with BECT.
